These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 11164157)

  • 1. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
    Kiratli BJ; Srinivas S; Perkash I; Terris MK
    Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.
    Conde FA; Sarna L; Oka RK; Vredevoe DL; Rettig MB; Aronson WJ
    Urology; 2004 Aug; 64(2):335-40. PubMed ID: 15302490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
    Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
    Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
    Bruder JM; Ma JZ; Basler JW; Welch MD
    Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen deprivation therapy for prostate cancer results in significant loss of bone density.
    Wei JT; Gross M; Jaffe CA; Gravlin K; Lahaie M; Faerber GJ; Cooney KA
    Urology; 1999 Oct; 54(4):607-11. PubMed ID: 10510915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy.
    Wang W; Yuasa T; Tsuchiya N; Maita S; Kumazawa T; Inoue T; Saito M; Ma Z; Obara T; Tsuruta H; Satoh S; Habuchi T
    Endocr Relat Cancer; 2008 Dec; 15(4):943-52. PubMed ID: 18667685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.
    Chen Z; Maricic M; Nguyen P; Ahmann FR; Bruhn R; Dalkin BL
    Cancer; 2002 Nov; 95(10):2136-44. PubMed ID: 12412167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies.
    Diamond TH; Higano CS; Smith MR; Guise TA; Singer FR
    Cancer; 2004 Mar; 100(5):892-9. PubMed ID: 14983482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].
    Deng J; Li W; Yang L; Wang L; Zou D
    Zhonghua Nan Ke Xue; 2004 Oct; 10(10):761-3. PubMed ID: 15562791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
    BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
    Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
    Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
    Yuasa T; Maita S; Tsuchiya N; Ma Z; Narita S; Horikawa Y; Yamamoto S; Yonese J; Fukui I; Takahashi S; Hatake K; Habuchi T
    Urology; 2010 May; 75(5):1131-7. PubMed ID: 20163839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
    Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The relationship between daily calcium intake and bone mineral density in men with prostate cancer.
    Planas J; Morote J; Orsola A; Salvador C; Trilla E; Cecchini L; Raventós CX
    BJU Int; 2007 Apr; 99(4):812-5; discussion 815-6. PubMed ID: 17378843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for bone loss with prostate cancer in Korean men not receiving androgen deprivation therapy.
    Kim SO; Kang TW; Kwon D; Park K; Ryu SB
    Int Braz J Urol; 2009; 35(2):183-8; discussion 189. PubMed ID: 19409122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values.
    Wadhwa VK; Weston R; Mistry R; Parr NJ
    BJU Int; 2009 Sep; 104(6):800-5. PubMed ID: 19338564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R; Lukka H; Cheung P; Corbett T; Briones-Urbina R; Vieth R; Ehrlich L; Kiss A; Danjoux C
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1239-45. PubMed ID: 23265571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.